Effect of esketamine pretreatment on thoracoscopic sympathetic dissociation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065216

Enrollment

Unknown

Registered

2022-10-31

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary palmar hyperhidrosis

Interventions

Experimental group:Intravenous administration of esketamine before anesthesia induction

Control group:Intravenous saline injection before anesthesia induction

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Age 18 to 60 years; (2)BMI 16 to 28 kg/m2 ; (3) ASA I-II grade; (4)Day surgery is performed with thoracoscopic sympathetic dissociation).

Exclusion criteria

Exclusion criteria: (1) Difficult airway; (2) Respiratory tract infections; (3) Severe liver and kidney dysfunction; (4) Neurological diseases;3.Severe cardiopulmonary insufficiency; (5) Cardiopulmonary insufficiency.

Design outcomes

Primary

Measure	Time frame
VAS scores at different postoperative moments;	—

Secondary

Measure	Time frame
Heart rate and mean arterial pressure at different times before, during, and after surgery;Wake up time and PACU dwell time;Postoperative adverse reactions(dizzy?Nausea and vomiting?hypertension?tachycardia?Itching of the skin);The amount of propofol and refentanil during surgery;	—

Countries

China

Contacts

Public ContactXie Wenqin

The First Hospital of Quanzhou, Fujian

xiewenqin9@126.com+86 13599269966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026